Email this article INTERMITTENT HORMONE THERAPY WITH ELIGARD IN PATIENTS WITH PROSTATE CANCER
- Authors: Alekseev B.Y.1, Krasheninnikov A.A.1, Nyushko K.M.1, Kalpinsky A.S.1, Kaprin A.D.1
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute
- Issue: Vol 10, No 1 (2014)
- Pages: 69-75
- Section: REVIEW
- Published: 30.03.2014
- URL: https://oncourology.abvpress.ru/oncur/article/view/23
- DOI: https://doi.org/10.17650/1726-9776-2014-10-1-69-75
- ID: 23
Cite item
Full Text
Abstract
Prostate cancer (PC) is one of the most burning problems of modern urologic oncology, which is attributable to the fact that the incidence of this pathology remains high. Hormone therapy (HT) is a basic treatment in patients with metastatic PC. Intermittent HT (IHT) is an effective and safe method for hormonal exposure in PC patients, as supported by the results of many trials. IHT may be recommended in the therapy of patients with PC in different clinical situations, including in patients with distant metastases. Eligard is recognized to be an effective and safe medicament to treat this category of patients. Its injection formulation once three or six months is easy-to-use for IHT.
About the authors
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute
Author for correspondence.
Email: byalekseev@mail.ru
Russian Federation
A. A. Krasheninnikov
P.A. Herzen Moscow Oncology Research Institute
Email: byalekseev@mail.ru
Russian Federation
K. M. Nyushko
P.A. Herzen Moscow Oncology Research Institute
Email: byalekseev@mail.ru
Russian Federation
A. S. Kalpinsky
P.A. Herzen Moscow Oncology Research Institute
Email: byalekseev@mail.ru
Russian Federation
A. D. Kaprin
P.A. Herzen Moscow Oncology Research Institute
Email: byalekseev@mail.ru
Russian Federation
References
Supplementary files
